October 10, 2024
CellCarta offers a full range of validated human IHC, multiplex IHC (mIHC) and multiplex immunofluorescence (mIF) assays. With sites accredited by CAP and CLIA certifications, we provide the highest standard of quality. Our team continually develops new biomarker assays and has experience with hundreds more than represented in the brochure.
Contact us for any custom development!
You might also be interested by
Posters
Development of a Pathologist Scoring Method to Determine Inflamed, Excluded or Desert Immune Phenotype in Carcinoma
March 5, 2025
Histopathology
More infoScientific Publications
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
January 27, 2025
Histopathology
More infoPosters
Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer
November 7, 2024
Histopathology
More infoCellTalk Blog
Optimal FFPE Tissue Fixation, Processing, and Embedding: A Comprehensive Guide
September 4, 2024
Histopathology
More info